SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Arthur Klausner to participate in the panel "Alternatives for Creating Value in a challenging time" at NASDAQ Healthcare Industry Forum in New York City
News | 12. 08. 2008
